All In Biotech

Drug Trial Radar · NCT05669599

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 592 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

592

Actual

Start

Jan 18, 2023

Primary completion

Oct 8, 2024

Study completion Dec 16, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jan 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).

Conditions

  • Obesity
  • Overweight
  • Type 2 Diabetes Mellitus

Interventions

  • Maridebart CafraglutideBiological

    Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

  • PlaceboDrug

    Participants will receive placebo by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 52 in Body WeightTime frame: Baseline and Week 52

Locations

78 sites in 12 countries. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research Mobile

    Mobile, Alabama

  • Foothills Research Center

    Phoenix, Arizona

  • HonorHealth

    Scottsdale, Arizona

  • Ark Clinical Research- Long Beach

    Long Beach, California

  • Ark Clinical Research- Tustin

    Tustin, California

  • Orange County Research Center

    Tustin, California

  • Diablo Clinical Research

    Walnut Creek, California

  • Alliance for Multispecialty Research Miami

    Coral Gables, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • East-West Medical Research

    Honolulu, Hawaii

  • University of Chicago

    Chicago, Illinois

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Alliance for Multispecialty Research Newton

    Newton, Kansas

  • Louisville Metabolic and Atherosclerosis Research Center

    Louisville, Kentucky

  • Tandem Clinical Research - Marrero

    Marrero, Louisiana

  • StudyMetrix Research

    City of Saint Peters, Missouri

  • Alliance for Multispecialty Research Kansas City

    Kansas City, Missouri

  • State University of New York Upstate Medical University

    Syracuse, New York

  • Lucas Research

    Morehead City, North Carolina

  • Research Innovations LLC dba Internal Medicine Care Inc

    Beavercreek, Ohio

  • The Christ Hospital

    Cincinnati, Ohio

  • Alliance for Multispecialty Research Norman

    Norman, Oklahoma

  • Medical Care LLC

    Elizabethton, Tennessee

  • PanAmerican Clinical Research LLC

    Brownsville, Texas

  • Headlands Research Brownsville

    Brownsville, Texas

  • Clinical Trials of Texas

    San Antonio, Texas

  • Diabetes and Glandular Disease Clinic

    San Antonio, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • Texas Diabetes Institute

    San Antonio, Texas

  • Royal Prince Alfred Hospital (RPAH) Clinic

    Camperdown, New South Wales, Australia

  • Clinical Medical and Analytical eXellence CMAX

    Adelaide, South Australia, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Austin Health, Heidelberg Repatriation Hospital

    Heidelberg Heights, Victoria, Australia

  • Baker Heart and Diabetes Institute

    Melbourne, Victoria, Australia

  • University of Calgary

    Calgary, Alberta, Canada

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, Canada

  • Centricity Research Vaughan Endocrinology

    Concord, Ontario, Canada

  • Institut Universitaire de cardiologie et de pneumologie de Quebec

    Québec, Quebec, Canada

  • Clinique des Maladies Lipidiques de Quebec Incorporated

    Québec, Quebec, Canada

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.